02616 CSTONE PHARMA-B
- 1.960
- -0.040-2.00%
CSTONE PHARMA-B News
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 2,269,500 SHARES, WITH ACCUMULATED PURCHASE TOTALLING 9,799,000 SHARES
CSTONE PHARMA-B: (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY NON-EXECUTIVE DIRECTOR MR. KENNETH WALTON HITCHNER III BY 2,219,500 SHARES
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 3,345,000 SHARES,WITH ACCUMULATED PURCHASE TOTALLING 7,529,500 SHARES
CSTONE PHARMA-B: (I) GRANT OF RESTRICTED SHARE UNITS UNDER THEPOST-IPO RSU SCHEME; AND(II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
CSTONE PHARMA-B: (1) PROPOSED GRANT OF OPTIONS TO A DIRECTOR ANDCHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP;(2) NOTICE OF EXTRAORDINARY GENERAL MEETING; AND(3) CLOSURE OF REGISTER OF MEMBERS FORTHE EXTRAORDINARY GENERAL MEETING
CSTONE PHARMA-B: BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING
CSTONE PHARMA-B: GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 460,000 SHARES, WITH ACCUMULATED PURCHASE TOTALLING 3,732,500 SHARES
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 501,000 SHARES, WITH ACCUMULATED PURCHASE TOTALLING 3,272,500 SHARES
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEFEXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CSTONE PHARMA-B: (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
CSTONE PHARMA-B: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
CSTONE PHARMA-B: (1) PROPOSED RE-GRANTS OF SHARE OPTIONS TO EXISTING GRANTEES UNDER THE POST-IPO ESOP; (2) PROPOSED GRANT OF SHARE OPTIONS TO A DIRECTOR AND CHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP; (3) PROPOSED AMENDMENTS TO THE POST-IPO ESOP; (4)
CSTONE PHARMA-B: PLACING OF NEW SHARES UNDER GENERAL MANDATE
CSTONE PHARMA-B: (I) PROPOSED CANCELLATION AND RE-GRANTS OF OPTIONSTO EXISTING GRANTEESUNDER THE POST-IPO ESOP; AND(II) PROPOSED AMENDMENTS TO THE SHARE INCENTIVE SCHEMES
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEFEXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
CSTONE PHARMA-B: GRANT OF OPTIONS PURSUANT TO THE POST-IPO ESOP
Analysis
Price Target
No Data
No Data